{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:36:29Z","timestamp":1786988189837,"version":"build-2736575974"},"reference-count":144,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T00:00:00Z","timestamp":1559606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.ekir.2019.06.002","type":"journal-article","created":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T04:07:12Z","timestamp":1561003632000},"page":"1043-1056","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":113,"title":["Strategies for Phosphate Control in Patients With CKD"],"prefix":"10.1016","volume":"4","author":[{"given":"Fellype Carvalho","family":"Barreto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela Veit","family":"Barreto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziad A.","family":"Massy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilman B.","family":"Dr\u00fceke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2019.06.002_bib1","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/ki.2011.47","article-title":"Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease","volume":"79","author":"Isakova","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2019.06.002_bib2","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.kint.2017.11.022","article-title":"The sodium phosphate cotransporter family and nicotinamide phosphoribosyltransferase contribute to the daily oscillation of plasma inorganic phosphate concentration","volume":"93","author":"Miyagawa","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2019.06.002_bib3","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.kint.2018.01.010","article-title":"The phosphate bucket list","volume":"93","author":"Isakova","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2019.06.002_bib4","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJM197709292971307","article-title":"Hyperphosphatemia in lactic acidosis","volume":"297","author":"O'Connor","year":"1977","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2019.06.002_bib5","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/0735-6757(92)90013-N","article-title":"Severe hyperphosphatemia associated with hemorrhagic shock","volume":"10","author":"Sternbach","year":"1992","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.ekir.2019.06.002_bib6","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/0002-9343(85)90053-1","article-title":"Dynamic changes in serum phosphorus levels in diabetic ketoacidosis","volume":"79","author":"Kebler","year":"1985","journal-title":"Am J Med"},{"key":"10.1016\/j.ekir.2019.06.002_bib7","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","article-title":"Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study","volume":"31","author":"Block","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2019.06.002_bib8","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1681\/ASN.2004070602","article-title":"Serum phosphate levels and mortality risk among people with chronic kidney disease","volume":"16","author":"Kestenbaum","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2019.06.002_bib9","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1161\/CIRCULATIONAHA.105.553198","article-title":"Relation between serum phosphate level and cardiovascular event rate in people with coronary disease","volume":"112","author":"Tonelli","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2019.06.002_bib10","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2019.06.002_bib11","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1093\/ndt\/gfm286","article-title":"High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients","volume":"22","author":"Voormolen","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2019.06.002_bib12","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1042\/CS20160807","article-title":"High phosphate induces a pro-inflammatory response by vascular smooth muscle cells and modulation by vitamin D derivatives","volume":"131","author":"Martinez-Moreno","year":"2017","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.ekir.2019.06.002_bib13","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/cvr\/cvs240","article-title":"Effects of phosphate on vascular function under normal conditions and influence of the uraemic state","volume":"96","author":"Six","year":"2012","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ekir.2019.06.002_bib14","first-page":"109697","article-title":"Arterial calcification in chronic kidney disease: key roles for calcium and phosphate","author":"Shanahan","year":"2011","journal-title":"Circ Res"},{"key":"10.1016\/j.ekir.2019.06.002_bib15","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1161\/ATVBAHA.111.231001","article-title":"Dietary phosphate modulates atherogenesis and insulin resistance in apolipoprotein E knockout mice\u2013brief report","volume":"31","author":"Ellam","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ekir.2019.06.002_bib16","doi-asserted-by":"crossref","first-page":"13701","DOI":"10.1038\/s41598-018-32065-2","article-title":"Increased phosphaturia accelerates the decline in renal function: a search for mechanisms","volume":"8","author":"Santamaria","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.ekir.2019.06.002_bib17","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ekir.2019.06.002_bib18","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1525-139X.2009.00581.x","article-title":"Parathyroid hormone, a uremic toxin","volume":"22","author":"Rodriguez","year":"2009","journal-title":"Semin Dial"},{"key":"10.1016\/j.ekir.2019.06.002_bib19","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/ki.2012.176","article-title":"Update on fibroblast growth factor 23 in chronic kidney disease","volume":"82","author":"Wolf","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2019.06.002_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","article-title":"KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease\u2013mineral and bone disorder (CKD-MBD)","volume":"7","year":"2017","journal-title":"Kidney Int Suppl"},{"issue":"113","key":"10.1016\/j.ekir.2019.06.002_bib21","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease\u2013mineral and bone disorder (CKD-MBD)","year":"2009","journal-title":"Kidney Int Suppl"},{"issue":"4 Suppl 3","key":"10.1016\/j.ekir.2019.06.002_bib22","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease","volume":"42","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2019.06.002_bib23","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1023\/A:1026224101580","article-title":"Phytase enzymology, applications, and biotechnology","volume":"25","author":"Lei","year":"2003","journal-title":"Biotechnol Lett"},{"key":"10.1016\/j.ekir.2019.06.002_bib24","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2215\/CJN.05040610","article-title":"Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease","volume":"6","author":"Moe","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2019.06.002_bib25","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1681\/ASN.2013101076","article-title":"The human response to acute enteral and parenteral phosphate loads","volume":"25","author":"Scanni","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2019.06.002_bib26","first-page":"303","article-title":"Extra-phosphate load from food additives in commonly eaten foods: a real and insidious danger for renal patients","volume":"21","author":"Benini","year":"2011","journal-title":"J\u00a0Ren Nutr"},{"key":"10.1016\/j.ekir.2019.06.002_bib27","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1053\/j.ajkd.2018.11.004","article-title":"Dietary phosphate and the forgotten kidney patient: a critical need for FDA regulatory action","volume":"73","author":"Calvo","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2019.06.002_bib28","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1681\/ASN.2010020221","article-title":"Low socioeconomic status associates with higher serum phosphate irrespective of race","volume":"21","author":"Gutierrez","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2019.06.002_bib29","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1475-2891-12-94","article-title":"Associations among total and food additive phosphorus intake and carotid intima-media thickness\u2013a cross-sectional study in a middle-aged population in southern Finland","volume":"12","author":"Itkonen","year":"2013","journal-title":"Nutr J"},{"key":"10.1016\/j.ekir.2019.06.002_bib30","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/ki.2015.67","article-title":"A\u00a0dearth of data: the problem of phosphorus in prescription medications","volume":"87","author":"Sherman","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2019.06.002_bib31","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/ki.1994.408","article-title":"Phosphorus and protein restriction and parathyroid function in chronic renal failure","volume":"46","author":"Combe","year":"1994","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2019.06.002_bib32","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1159\/000188606","article-title":"Long-term control of hyperparathyroidism in advanced renal failure by low-phosphorus low-protein diet supplemented with calcium (without changes in plasma calcitriol)","volume":"70","author":"Combe","year":"1995","journal-title":"Nephron"},{"key":"10.1016\/j.ekir.2019.06.002_bib33","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1056\/NEJM198903303201310","article-title":"The modification of diet in renal disease study","volume":"320","author":"Klahr","year":"1989","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2019.06.002_bib34","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3945\/ajcn.2008.26665","article-title":"Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease?","volume":"88","author":"Shinaberger","year":"2008","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.ekir.2019.06.002_bib35","first-page":"504","article-title":"The effect of various boiling conditions on reduction of phosphorus and protein in meat","volume":"25","author":"Ando","year":"2015","journal-title":"J\u00a0Ren Nutr"},{"key":"10.1016\/j.ekir.2019.06.002_bib36","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.3945\/ajcn.114.085498","article-title":"Effect of dietary phosphate intake on the circadian rhythm of serum phosphate concentrations in chronic kidney disease: a crossover study","volume":"100","author":"Ix","year":"2014","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.ekir.2019.06.002_bib37","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1053\/j.ajkd.2016.08.029","article-title":"Phosphorus additives and albuminuria in early stages of CKD: a randomized controlled trial","volume":"69","author":"Chang","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2019.06.002_bib38","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/hdi.12315","article-title":"Phosphate binder pill burden, patient-reported non-adherence, and mineral bone disorder markers: findings from the DOPPS","volume":"20","author":"Fissell","year":"2016","journal-title":"Hemodial Int"},{"key":"10.1016\/j.ekir.2019.06.002_bib39","first-page":"673","article-title":"Adherence to phosphate binders in hemodialysis patients: prevalence and determinants","volume":"27","author":"Van Camp","year":"2014","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.ekir.2019.06.002_bib40","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1056\/NEJM197601222940402","article-title":"The dialysis encephalopathy syndrome. Possible aluminum intoxication","volume":"294","author":"Alfrey","year":"1976","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2019.06.002_bib41","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1471-2369-12-20","article-title":"Do aluminium-based phosphate binders continue to have a role in contemporary nephrology practice?","volume":"12","author":"Mudge","year":"2011","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2019.06.002_bib42","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0140-6736(82)92678-2","article-title":"Water supply aluminium concentration, dialysis dementia, and effect of reverse-osmosis water treatment","volume":"2","author":"Davison","year":"1982","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2019.06.002_bib43","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0272-6386(85)80091-3","article-title":"Clinical and laboratory features of aluminum-related bone disease: differences between sporadic and \"epidemic\" forms of the syndrome","volume":"6","author":"Norris","year":"1985","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2019.06.002_bib44","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/aor.12478","article-title":"The fatal interplay of aluminum and citrate in chronic renal failure: a lesson from three decades ago","volume":"39","author":"Bakir","year":"2015","journal-title":"Artif Organs"},{"key":"10.1016\/j.ekir.2019.06.002_bib45","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1001\/archneur.1981.00510100084016","article-title":"Encephalopathy in infants and children with chronic renal disease","volume":"38","author":"Foley","year":"1981","journal-title":"Arch Neurol"},{"key":"10.1016\/j.ekir.2019.06.002_bib46","first-page":"111","article-title":"Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients","volume":"45","author":"Janssen","year":"1996","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.ekir.2019.06.002_bib47","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/ndt\/6.2.98","article-title":"Comparison of calcium carbonate and aluminium hydroxide as phosphate binders on biochemical bone markers, PTH(1-84), and bone mineral content in dialysis patients","volume":"6","author":"Jespersen","year":"1991","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2019.06.002_bib48","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1159\/000168713","article-title":"Calcium acetate versus calcium carbonate for the control of serum phosphorus in hemodialysis patients","volume":"14","author":"Almirall","year":"1994","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.ekir.2019.06.002_bib49","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/ndt\/9.8.1121","article-title":"Calcium acetate versus calcium carbonate as phosphate-binding agents in chronic haemodialysis","volume":"9","author":"Pflanz","year":"1994","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2019.06.002_bib50","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2369-12-9","article-title":"A\u00a0randomized, double-blind, placebo-controlled trial of calcium acetate on serum phosphorus concentrations in patients with advanced non-dialysis-dependent chronic kidney disease","volume":"12","author":"Qunibi","year":"2011","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2019.06.002_bib51","first-page":"S114","article-title":"Calcium carbonate, an aluminum-free agent for control of hyperphosphatemia, hypocalcemia, and hyperparathyroidism in uremia","volume":"18","author":"Fournier","year":"1986","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.ekir.2019.06.002_bib52","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/ki.2012.403","article-title":"Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease","volume":"83","author":"Hill","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2019.06.002_bib53","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/ki.2011.490","article-title":"Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets","volume":"81","author":"Spiegel","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2019.06.002_bib54","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1093\/ndt\/gfg414","article-title":"Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality","volume":"18","author":"London","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2019.06.002_bib55","doi-asserted-by":"crossref","first-page":"F891","DOI":"10.1152\/ajprenal.00163.2014","article-title":"A\u00a0current understanding of vascular calcification in CKD","volume":"307","author":"Paloian","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.ekir.2019.06.002_bib56","first-page":"416","article-title":"Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study","volume":"17","author":"Spiegel","year":"2007","journal-title":"J\u00a0Ren Nutr"},{"issue":"Suppl 1","key":"10.1016\/j.ekir.2019.06.002_bib57","doi-asserted-by":"crossref","first-page":"i52","DOI":"10.1093\/ndtplus\/sfr167","article-title":"Magnesium and outcomes in patients with chronic kidney disease: focus on vascular calcification, atherosclerosis and survival","volume":"5","author":"Massy","year":"2012","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2019.06.002_bib58","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1038\/ki.2013.34","article-title":"Effect of a magnesium-based phosphate binder on medial calcification in a rat model of uremia","volume":"83","author":"De Schutter","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2019.06.002_bib59","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1542-4758.2009.00364.x","article-title":"Long-term effects of magnesium carbonate on coronary artery calcification and bone mineral density in hemodialysis patients: a pilot study","volume":"13","author":"Spiegel","year":"2009","journal-title":"Hemodial Int"},{"key":"10.1016\/j.ekir.2019.06.002_bib60","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1007\/s11255-014-0751-9","article-title":"Magnesium retards the progress of the arterial calcifications in hemodialysis patients: a pilot study","volume":"46","author":"Tzanakis","year":"2014","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.ekir.2019.06.002_bib61","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1093\/ndt\/gfq292","article-title":"Evaluation of calcium acetate\/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability","volume":"25","author":"de Francisco","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2019.06.002_bib62","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3747\/pdi.2013.00129","article-title":"MgCaCO3 versus CaCO3 in peritoneal dialysis patients\u2013a cross-over pilot trial","volume":"35","author":"Evsanaa","year":"2015","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.ekir.2019.06.002_bib63","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1681\/ASN.2018111150","article-title":"A\u00a0randomized trial of magnesium oxide and oral carbon adsorbent for coronary artery calcification in predialysis CKD","volume":"30","author":"Sakaguchi","year":"2019","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2019.06.002_bib64","first-page":"265","article-title":"Effects of oral activated charcoal on hyperphosphatemia and vascular calcification in Chinese patients with stage 3-4 chronic kidney disease","volume":"32","author":"Gao","year":"2019","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.ekir.2019.06.002_bib65","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S0272-6386(99)70221-0","article-title":"A\u00a0comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients","volume":"33","author":"Bleyer","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2019.06.002_bib66","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1111\/j.1523-1755.2004.00590.x","article-title":"Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study)","volume":"65","author":"Qunibi","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2019.06.002_bib67","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/ndt\/gfn488","article-title":"Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis","volume":"24","author":"Evenepoel","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2019.06.002_bib68","first-page":"82","article-title":"Comparison of sevelamer and calcium carbonate on endothelial function and inflammation in patients on peritoneal dialysis","volume":"39","author":"Chennasamudram","year":"2013","journal-title":"J\u00a0Ren Care"},{"key":"10.1016\/j.ekir.2019.06.002_bib69","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1053\/j.ajkd.2010.10.055","article-title":"Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients","volume":"57","author":"Kakuta","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2019.06.002_bib70","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/ckj\/sfx074","article-title":"Sevelamer reduces endothelial inflammatory response to advanced glycation end products","volume":"11","author":"Gregorio","year":"2018","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2019.06.002_bib71","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1046\/j.1523-1755.2002.00459.x","article-title":"Bile acid binding to sevelamer HCl","volume":"62","author":"Braunlin","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2019.06.002_bib72","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1053\/jarr.2003.50016","article-title":"Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients","volume":"10","author":"Burke","year":"2003","journal-title":"Adv Ren Replace Ther"},{"key":"10.1016\/j.ekir.2019.06.002_bib73","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1111\/dom.13272","article-title":"Glucose-lowering effects and mechanisms of the bile acid-sequestering resin sevelamer","volume":"20","author":"Bronden","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ekir.2019.06.002_bib74","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/j.ajkd.2011.12.001","article-title":"Potential interaction between sevelamer and fat-soluble vitamins: a hypothesis","volume":"59","author":"Susantitaphong","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2019.06.002_bib75","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1111\/j.1523-1755.2005.00600.x","article-title":"Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis","volume":"68","author":"Block","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2019.06.002_bib76","doi-asserted-by":"crossref","first-page":"c273","DOI":"10.1159\/000170783","article-title":"Phosphate binder impact on bone remodeling and coronary calcification\u2013results from the BRiC study","volume":"110","author":"Barreto","year":"2008","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.ekir.2019.06.002_bib77","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1053\/j.ajkd.2008.02.298","article-title":"A\u00a01-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study","volume":"51","author":"Qunibi","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2019.06.002_bib78","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1523-1755.2002.00434.x","article-title":"Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients","volume":"62","author":"Chertow","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2019.06.002_bib79","first-page":"CD006023","article-title":"Phosphate binders for preventing and treating chronic kidney disease\u2212mineral and bone disorder (CKD-MBD)","volume":"8","author":"Ruospo","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ekir.2019.06.002_bib80","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1185\/030079907X242719","article-title":"A\u00a0comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate","volume":"23","author":"Sprague","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ekir.2019.06.002_bib81","doi-asserted-by":"crossref","first-page":"232","DOI":"10.2215\/CJN.06800615","article-title":"Sevelamer versus calcium-based binders for treatment of hyperphosphatemia in CKD: a meta-analysis of randomized controlled trials","volume":"11","author":"Patel","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2019.06.002_bib82","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.jval.2011.05.043","article-title":"Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a US payer perspective","volume":"14","author":"Park","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.ekir.2019.06.002_bib83","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/1744-9987.12068","article-title":"Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia","volume":"18","author":"Akizawa","year":"2014","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.ekir.2019.06.002_bib84","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1471-2369-12-49","article-title":"Conversion to lanthanum carbonate monotherapy effectively controls serum phosphorus with a reduced tablet burden: a multicenter open-label study","volume":"12","author":"Vemuri","year":"2011","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2019.06.002_bib85","doi-asserted-by":"crossref","first-page":"382","DOI":"10.5414\/CN107330","article-title":"Efficacy and safety of lanthanum carbonate in German patients on dialysis","volume":"78","author":"Dellanna","year":"2012","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.ekir.2019.06.002_bib86","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1007\/s12325-013-0077-5","article-title":"The real-world dose-relativity of sevelamer hydrochloride and lanthanum carbonate monotherapy in patients with end-stage renal disease","volume":"30","author":"Wilson","year":"2013","journal-title":"Adv Ther"},{"key":"10.1016\/j.ekir.2019.06.002_bib87","doi-asserted-by":"crossref","first-page":"181","DOI":"10.5414\/CN108269","article-title":"Efficacy and safety of lanthanum carbonate in pre-dialysis CKD patients with hyperphosphatemia: a randomized trial","volume":"82","author":"Takahara","year":"2014","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.ekir.2019.06.002_bib88","doi-asserted-by":"crossref","first-page":"216","DOI":"10.5414\/CN107257","article-title":"Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: a crossover study","volume":"78","author":"Toida","year":"2012","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.ekir.2019.06.002_bib89","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/1471-2369-14-226","article-title":"Efficacy and safety of lanthanum carbonate on chronic kidney disease\u2212mineral and bone disorder in dialysis patients: a systematic review","volume":"14","author":"Zhang","year":"2013","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2019.06.002_bib90","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.gie.2012.11.002","article-title":"Pharmacobezoar in a patient on an oral phosphate binder","volume":"77","author":"Black","year":"2013","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.ekir.2019.06.002_bib91","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/j.1523-1755.2005.00171.x","article-title":"Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration","volume":"67","author":"Lacour","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2019.06.002_bib92","first-page":"286","article-title":"Lanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease stage 5 receiving hemodialysis","volume":"71","author":"Hutchison","year":"2009","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.ekir.2019.06.002_bib93","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1093\/ndt\/gfl146","article-title":"Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up","volume":"21","author":"Spasovski","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2019.06.002_bib94","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1681\/ASN.2014020212","article-title":"Ferric citrate controls phosphorus and delivers iron in patients on dialysis","volume":"26","author":"Lewis","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2019.06.002_bib95","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1681\/ASN.2014080842","article-title":"Ferric citrate reduces intravenous iron and erythropoiesis-stimulating agent use in ESRD","volume":"26","author":"Umanath","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2019.06.002_bib96","first-page":"329","article-title":"Phosphate binders in chronic kidney disease: a systematic review of recent data","volume":"29","author":"Floege","year":"2016","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.ekir.2019.06.002_bib97","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2174\/1389200216666150206124424","article-title":"Preclinical pharmacokinetics, pharmacodynamics and safety of sucroferric oxyhydroxide","volume":"15","author":"Cozzolino","year":"2014","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.ekir.2019.06.002_bib98","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1093\/ndt\/gfv006","article-title":"Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients","volume":"30","author":"Floege","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2019.06.002_bib99","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/ki.2014.58","article-title":"A\u00a0phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients","volume":"86","author":"Floege","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2019.06.002_bib100","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/ndt\/gfw242","article-title":"Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide","volume":"32","author":"Covic","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2019.06.002_bib101","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1093\/ckj\/sfy077","article-title":"Evaluation of changes in ferritin levels during sucroferric oxyhydroxide treatment","volume":"12","author":"Koiwa","year":"2019","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2019.06.002_bib102","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000490903","article-title":"Effect of sucroferric oxyhydroxide on fibroblast growth factor 23 levels in hemodialysis patients","volume":"140","author":"Otsuki","year":"2018","journal-title":"Nephron"},{"key":"10.1016\/j.ekir.2019.06.002_bib103","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(13)60897-1","article-title":"Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis","volume":"382","author":"Jamal","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2019.06.002_bib104","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1159\/000488700","article-title":"Effect of lanthanum carbonate on all-cause mortality in patients receiving maintenance hemodialysis: a meta-analysis of randomized controlled trials","volume":"43","author":"Wang","year":"2018","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.ekir.2019.06.002_bib105","doi-asserted-by":"crossref","first-page":"F285","DOI":"10.1152\/ajprenal.00508.2009","article-title":"Phosphate homeostasis and the renal-gastrointestinal axis","volume":"299","author":"Marks","year":"2010","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.ekir.2019.06.002_bib106","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.mam.2012.07.007","article-title":"Phosphate transporters of the SLC20 and SLC34 families","volume":"34","author":"Forster","year":"2013","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.ekir.2019.06.002_bib107","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1681\/ASN.2012030223","article-title":"Effects of phosphate binders in moderate CKD","volume":"23","author":"Block","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2019.06.002_bib108","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1681\/ASN.2011121213","article-title":"Npt2b deletion attenuates hyperphosphatemia associated with CKD","volume":"23","author":"Schiavi","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2019.06.002_bib109","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/ndt\/14.5.1195","article-title":"Nicotinamide inhibits sodium-dependent phosphate cotransport activity in rat small intestine","volume":"14","author":"Katai","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2019.06.002_bib110","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1093\/ndt\/gfh781","article-title":"Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure","volume":"20","author":"Eto","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2019.06.002_bib111","doi-asserted-by":"crossref","first-page":"582","DOI":"10.2215\/CJN.07341009","article-title":"Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial","volume":"5","author":"Maccubbin","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2019.06.002_bib112","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/j.1523-1755.2004.00482.x","article-title":"Nicotinamide suppresses hyperphosphatemia in hemodialysis patients","volume":"65","author":"Takahashi","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2019.06.002_bib113","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2215\/CJN.04211007","article-title":"A\u00a0randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients","volume":"3","author":"Cheng","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2019.06.002_bib114","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1093\/ndt\/gfx249","article-title":"Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study","volume":"32","author":"Lenglet","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2019.06.002_bib115","doi-asserted-by":"crossref","unstructured":"Massy ZA, Drueke TB. Vascular calcification - any place left for nicotinamide [epub ahead of print]? Nephrol Dial Transplant. https:\/\/doi.org\/10.1093\/ndt\/gfz057. Accessed June 21, 2019.","DOI":"10.1093\/ndt\/gfz057"},{"key":"10.1016\/j.ekir.2019.06.002_bib116","doi-asserted-by":"crossref","unstructured":"Kaesler N, Goettsch C, Weis D. et al. Magnesium but not nicotinamide prevents vascular calcification in experimental uraemia [e-pub ahead of print]. Nephrol Dial Transplant. https:\/\/doi.org\/10.1093\/ndt\/gfy410. Accessed June 21, 2019.","DOI":"10.1093\/ndt\/gfy410"},{"key":"10.1016\/j.ekir.2019.06.002_bib117","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1681\/ASN.2014030317","article-title":"Gastrointestinal inhibition of sodium-hydrogen exchanger 3 reduces phosphorus absorption and protects against vascular calcification in CKD","volume":"26","author":"Labonte","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2019.06.002_bib118","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1681\/ASN.2016080855","article-title":"Effect of tenapanor on serum phosphate in patients receiving hemodialysis","volume":"28","author":"Block","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2019.06.002_bib119","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1681\/ASN.2018080832","article-title":"Efficacy and safety of tenapanor in patients with hyperphosphatemia receiving maintenance hemodialysis: a randomized phase 3 trial","volume":"30","author":"Block","year":"2019","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2019.06.002_bib120","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/ki.1986.252","article-title":"The absorption of dietary phosphorus and calcium in hemodialysis patients","volume":"30","author":"Ramirez","year":"1986","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2019.06.002_bib121","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1093\/ndt\/17.6.1037","article-title":"Estimating phosphate removal in haemodialysis: an additional tool to quantify dialysis dose","volume":"17","author":"Gutzwiller","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2019.06.002_bib122","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1681\/ASN.2011070688","article-title":"Effects of frequent hemodialysis on measures of CKD mineral and bone disorder","volume":"23","author":"Daugirdas","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2019.06.002_bib123","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.2215\/CJN.05560809","article-title":"Long-term outcomes in online hemodiafiltration and high-flux hemodialysis: a comparative analysis","volume":"4","author":"Vilar","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2019.06.002_bib124","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1093\/ndt\/gfy035","article-title":"Haemodialysis or haemodiafiltration: that is the question","volume":"33","author":"Locatelli","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2019.06.002_bib125","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/nep.12039","article-title":"Phosphate handling by end-stage kidneys and benefits of residual renal function on phosphate removal in patients on haemodialysis","volume":"18","author":"Iwasawa","year":"2013","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.ekir.2019.06.002_bib126","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1053\/j.ajkd.2003.12.032","article-title":"Hyperphosphatemia in Chinese peritoneal dialysis patients with and without residual kidney function: what are the implications?","volume":"43","author":"Wang","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2019.06.002_bib127","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2215\/CJN.04480510","article-title":"Role of residual renal function in phosphate control and anemia management in chronic hemodialysis patients","volume":"6","author":"Penne","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2019.06.002_bib128","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1093\/ndt\/gfp220","article-title":"Phosphate levels\u2013time for a rethink?","volume":"24","author":"Becker","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2019.06.002_bib129","first-page":"351","article-title":"Circadian variation of mineral and bone parameters in end-stage renal disease","volume":"28","author":"Trivedi","year":"2015","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.ekir.2019.06.002_bib130","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.2215\/CJN.09471209","article-title":"Variability of parathyroid hormone and other markers of bone mineral metabolism in patients receiving hemodialysis","volume":"5","author":"Gardham","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2019.06.002_bib131","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1681\/ASN.2007060673","article-title":"Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD","volume":"19","author":"Isakova","year":"2008","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2019.06.002_bib132","doi-asserted-by":"crossref","first-page":"286","DOI":"10.2215\/CJN.05420709","article-title":"Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?","volume":"5","author":"Oliveira","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2019.06.002_bib133","doi-asserted-by":"crossref","first-page":"F1181","DOI":"10.1152\/ajprenal.00271.2017","article-title":"Coupling between phosphate and calcium homeostasis: a mathematical model","volume":"313","author":"Granjon","year":"2017","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.ekir.2019.06.002_bib134","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/ki.2015.290","article-title":"Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production","volume":"89","author":"David","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2019.06.002_bib135","doi-asserted-by":"crossref","first-page":"c74","DOI":"10.1159\/000319650","article-title":"Fibroblast growth factor 23 in hemodialysis patients: effects of phosphate binder, calcitriol and calcium concentration in the dialysate","volume":"117","author":"Cancela","year":"2011","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.ekir.2019.06.002_bib136","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/ndt\/gfy127","article-title":"Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease\u2212mineral bone disorder parameters in dialysis patients","volume":"34","author":"Ketteler","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2019.06.002_bib137","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1007\/s00467-012-2175-z","article-title":"Phosphate homeostasis and its role in bone health","volume":"27","author":"Goretti Penido","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2019.06.002_bib138","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.kint.2015.12.004","article-title":"Changing bone patterns with progression of chronic kidney disease","volume":"89","author":"Drueke","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2019.06.002_bib139","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"Block","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2019.06.002_bib140","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis","volume":"367","author":"Chertow","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2019.06.002_bib141","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1001\/jama.2016.19468","article-title":"Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial","volume":"317","author":"Block","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ekir.2019.06.002_bib142","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1681\/ASN.V61132","article-title":"Low-calcium dialysate stimulates parathormone secretion and its long-term use worsens secondary hyperparathyroidism","volume":"6","author":"Fernandez","year":"1995","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2019.06.002_bib143","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/sj.ki.5001666","article-title":"Reversal of adynamic bone disease by lowering of dialysate calcium","volume":"70","author":"Haris","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2019.06.002_bib144","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1093\/ndt\/gfp597","article-title":"Effects of bone remodelling on calcium mass transfer during haemodialysis","volume":"25","author":"Karohl","year":"2010","journal-title":"Nephrol Dial Transplant"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024919313609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024919313609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T03:24:22Z","timestamp":1762831462000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024919313609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":144,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S2468024919313609"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2019.06.002","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Strategies for Phosphate Control in Patients With CKD","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2019.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}